Prothena Corporation plc (PRTA)
Summary
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $1.1 per share a year ago.
Prothena Down 40% Year to Date: What Lies Ahead for the Stock?
Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.
Prothena Corporation plc (PRTA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Prothena Corporation plc ever had a stock split?
Prothena Corporation plc Profile
| Biotechnology Industry | Healthcare Sector | Gene G. Kinney CEO | NASDAQ (NGS) Exchange | G72800108 CUSIP |
| IE Country | 163 Employees | - Last Dividend | - Last Split | 21 Dec 2012 IPO Date |
Overview
Prothena Corporation plc is a pioneering force in the biotechnology space, concentrating its efforts on the discovery and development of groundbreaking therapies targeted at diseases caused by protein dysregulation. As a late-stage clinical biotechnology entity based in Dublin, Ireland, and incorporated in 2012, Prothena has made significant strides in addressing some of the most challenging neurodegenerative diseases and related conditions. Leveraging a deep understanding of protein dysregulation, the company has embarked on several ambitious projects, including clinical trials aimed at tackling conditions such as AL amyloidosis, Parkinson's disease, ATTR amyloidosis, and Alzheimer’s disease through innovative therapeutic antibodies and vaccines. With a robust pipeline fueled by both in-house research and strategic partnerships with industry giants such as F. Hoffmann-La Roche Ltd. and Bristol-Myers Squibb, Prothena stands at the forefront of developing promising treatments for diseases with substantial unmet medical needs.
Products and Services
Prothena Corporation plc's dedication to addressing protein dysregulation has culminated in a diverse portfolio of investigational therapies at various stages of clinical development. These include:
- Birtamimab: A humanized antibody in Phase III clinical trials aimed at treating AL amyloidosis, a condition characterized by the abnormal deposition of amyloid proteins in tissues and organs.
- Prasinezumab: In partnership with F. Hoffmann-La Roche Ltd., this humanized monoclonal antibody targets α-synuclein and is currently in Phase IIb clinical trials for Parkinson's disease and other synucleinopathies, diseases related to the accumulation of α-synuclein protein in the brain.
- NNC6019: An antibody in Phase II clinical development for the treatment of ATTR amyloidosis, a disease where misfolded transthyretin proteins accumulate as amyloid fibrils in various organs.
- BMS-986446 and PRX012: Both in Phase I clinical trials, these antibodies are developed in collaboration with Bristol-Myers Squibb, targeting tau and amyloid-beta proteins, respectively, for the treatment of Alzheimer’s disease.
- PRX123: A dual Aβ-Tau vaccine for Alzheimer's disease prevention and treatment, which is currently in the discovery and preclinical stage, showcasing Prothena’s forward-thinking in addressing the dual pathological features of Alzheimer's disease.
- PRX019: Targeting neurodegenerative diseases, this antibody is designed to combat conditions characterized by the pathological aggregation of misfolded proteins, currently in preclinical development.
- TDP-43: Focused on the treatment of amyotrophic lateral sclerosis (ALS), this program is in the early stages of development, aiming at a protein implicated in the disease's pathology.
These investigational products reflect Prothena’s commitment to innovative treatments that address the underlying causes of debilitating diseases, with the potential to significantly impact patient care.
Contact Information
